BIODESIX, INC. Total Liabilities and Equity
BIODESIX, INC. (BDSX) had Total Liabilities and Equity of $95.33 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-05
- 2026-06-30: Liabilities and Equity $95.33M.
- 2026-03-31: Liabilities and Equity $94.64M.
- 2025-12-31: Liabilities and Equity $87.48M.
- 2025-09-30: Liabilities and Equity $88.72M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $95.33M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $94.64M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $87.48M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $88.72M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $87.74M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $86.24M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $97.24M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $102.74M 10-Q · filed 2024-11-01 | |
| 2024-06-30 | $115.84M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $87.20M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $99.10M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $86.79M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $77.62M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $80.79M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $92.91M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $63.20M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $75.23M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $61.65M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $76.10M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $90.00M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $101.80M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $115.49M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $121.07M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $46.55M 10-Q · filed 2020-12-10 | |
| 2019-12-31 | $45.03M 10-K · filed 2021-03-16 | $41.63M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |